After watching Martin Shkreli raise the price of a drug by more than 550% in 2015, Intermountain’s Dan Liljenquist had the same thought as the rest of America: Is this really happening? So the system decided to create a nonprofit generic drug company that Liljenquist calls a “first-of-its-kind societal asset.”
AHIP18: How Intermountain plans to fight pharmaceutical monopolies as a generic drugmaker
